Glucocorticoid Use in Patients Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
Songsong Yu,Shuang Li,Jie Zhang,Qiuhong Fang
DOI: https://doi.org/10.2147/copd.s436326
2024-02-13
International Journal of COPD
Abstract:Songsong Yu, 1 Shuang Li, 2 Jie Zhang, 3 Qiuhong Fang 4 1 Department of Emergency, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China; 2 Department of Health Management Institute, NO.2 Medical Centre, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China; 3 Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China; 4 Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China Correspondence: Qiuhong Fang, Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gong Ti Nan Lu, Chaoyang District, Beijing, 100020, People's Republic of China, Email Objective of the Study: Systemic glucocorticoid therapy can improve the outcomes of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The study tried to investigate the use of glucocorticoids in AECOPD patients and the factors associated with the physicians' choice. Methodology: Patients with AECOPD over two periods were divided by the year of 2017 when GOLD and ERS/ATS Guideline for COPD were updated. Data of patients regarding the study was retrieved from medical records. Descriptive statistical analysis was used for the illustration of glucocorticoids use, and hypothesis testing for comparison over the periods. Results: Between 2010 and 2016, the proportion of ICS use was 522/640 (81.6%) and 341/452 (75.4%) between 2017 and 2020. COPD severity (GOLD C/D classification), bronchial asthma, percentage of neutrophils, and higher PaCO 2 were factors associated with physicians' prescription of systemic glucocorticoids between 2010 and 2016. While the use of ICS at the stable stage, counts of neutrophils, and higher PaCO 2 were influencing factors between 2017 and 2020. Over the two periods, 1-year recurrent rate decreased from 32.4% to 20.9%, with a significant statistical difference ( P < 0.001). Conclusion: The optimized use of glucocorticoids was found after the publishment of 2017 ERS/ATS Guideline for COPD, this improvement was associated with a decreased 1-year recurrence rate among AECOPD patients at our institution, underscoring the positive impact of guideline updates on patient outcomes. Keywords: chronic obstructive pulmonary disease, acute exacerbation, glucocorticoids, treatment selection Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) involves inflammatory responses in the airway and is a major cause of hospitalization and mortality. 1–3 Systemic glucocorticoids can improve pulmonary function and oxygenation in patients with AECOPD, shorten recovery time and hospitalization, and reduce the failure rate of early treatments. 4 Systemic glucocorticoids are recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 4 but no detailed descriptions of time, dosage, mode, and duration of systemic glucocorticoid treatment are provided. In addition, glucocorticoids are associated with significant adverse effects. 4,5 Peripheral blood eosinophil ratio ≥2% can be used to determine who might achieve a better response to systemic glucocorticoids, 6,7 but prospective studies might not reflect the real-world situation. A retrospective observational study in China showed that among patients hospitalized with AECOPD, 9.8% did not receive glucocorticoids, 38% received only inhaled corticosteroids, and 56% were treated with systemic glucocorticoids, of whom 40.5% received inhaled and systemic corticosteroids simultaneously. 1 Unfortunately, in that previous study, detailed information on systemic glucocorticoids was not provided (eg when did the first inhaled glucocorticoids treatment fail, the sequential use of systemic after inhaled glucocorticoids, and the simultaneous use of inhaled and systemic glucocorticoids). Although systemic glucocorticoids in patients with AECOPD were recommended by guidelines, 4,5 treatment of a number of patients was inconsistent with those guidelines. 1 Therefore, the characterization of the actual situation and the understanding of why some patients are not treated according to guidelines is essential to formulate a management strategy that fits the actual reality. In addition, COPD is a heterogeneous disease within a given population of patients, and there are differences among ethnic groups. 4 Future more, with the update of GOLD and ERS/ATS Guideline f -Abstract Truncated-
respiratory system